ÂÜÀòÂÒÂ×

Jean-François Morin is the current director at Sensorion and has over eighteen years of experience in the biotechnology field. Jean-François began their career as an investment director for Bpifrance where they were responsible for life sciences investments and venture capital. During their time there, they also served on the board of Egle Therapeutics and ONA Therapeutics. In addition, they were a board observer for Orphalan and TISSIUM.

Most recently, they have been with Sensorion for eight years where they are also a board member and the president of the audit committee. Under their leadership, Sensorion has become a biopharmaceutical company committed to finding targeted and innovative treatments for inner ear disease.

Jean-François Morin has dedicated their career to developing new treatments for rare, genetic diseases. Their experience and expertise have made him a valuable asset to the biotechnology community.